By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced




Founder: Joshua Boger

CEO: Jeffrey Leiden

CMO (Medical): Jeffrey Chodakewitz

CFO: Ian Smith

CSO (Scientific): David Altshuler


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes? 10/18/2016 6:27:05 AM
Drug Pricing Woes Hit Vertex (VRTX) as One Mom Travels to Boston to Take on CEO 10/11/2016 6:39:13 AM
Vertex (VRTX) To Announce Third Quarter 2016 Financial Results On October 25 10/7/2016 10:59:08 AM
Vertex (VRTX) Release: FDA Approves ORKAMBI (Lumacaftor/Ivacaftor) For Use In Children With Cystic Fibrosis Ages 6 Through 11 Who Have Two Copies Of The F508del Mutation 9/29/2016 10:32:45 AM
Vertex (VRTX) TV Show Seeks Help From Boston Heavyweights Like Matt Damon or Mark Wahlberg 9/21/2016 7:25:58 AM
Vertex (VRTX) Looks To Cash In On Its Rich Drug Pipeline 9/16/2016 7:12:28 AM
Vertex (VRTX) To Present At Upcoming Investor Conferences 9/12/2016 12:03:18 PM
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study 8/16/2016 6:41:24 AM
Ophthotech Corporation (OPHT) Announces Election Of Ian F. Smith, Vertex (VRTX) Executive Vice President And Chief Financial Officer, To Its Board Of Directors 8/2/2016 11:22:18 AM
Vertex (VRTX) Reports Second Quarter 2016 Financial Results 7/28/2016 10:47:35 AM